Warner Chilcott acquires Dong-A's udenafil for US
This article was originally published in Scrip
Executive Summary
Dong-A PharmTechhas licensed its erectile dysfunction product udenafil exclusively to Warner Chilcottfor development and marketing in the US. The oral PDE5 inhibitor was approved as Zydena in South Korea in 2005 and in Russia last year, and Dong-A has already completed a Phase II US development programme. The South Korean firm will receive undisclosed up-front and milestone payments from Warner Chilcott, which already markets a range of oral contraceptives and women's health products.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.